Clinical uses of GM-CSF, a critical appraisal and update

Martha Arellano, Sagar LonialEmory University, Winship Cancer Institute, Atlanta, GA, USAAbstract: The role of granulocyte-macrophage-colony-stimulating factor (GM-CSF) in the supportive care of cancer patients has been evaluated with promising results. More recently, GM-CSF has been added to regime...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martha Arellano, Sagar Lonial
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/32953b4d00e0411a88651813463f32b8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32953b4d00e0411a88651813463f32b8
record_format	dspace
spelling	oai:doaj.org-article:32953b4d00e0411a88651813463f32b82021-12-02T02:00:18ZClinical uses of GM-CSF, a critical appraisal and update1177-54751177-5491https://doaj.org/article/32953b4d00e0411a88651813463f32b82008-03-01T00:00:00Zhttp://www.dovepress.com/clinical-uses-of-gm-csf-a-critical-appraisal-and-update-a50https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Martha Arellano, Sagar LonialEmory University, Winship Cancer Institute, Atlanta, GA, USAAbstract: The role of granulocyte-macrophage-colony-stimulating factor (GM-CSF) in the supportive care of cancer patients has been evaluated with promising results. More recently, GM-CSF has been added to regimens for the mobilization of hematopoietic progenitor cells. An expanding role for GM-CSF in regulating immune responses has been recognized based upon its activity on the development and maturation of antigen presenting cells and its capability for skewing the immune system toward Th1-type responses. GM-CSF has been shown to preferentially enhance both the numbers and activity of type 1 dendritic cells (DC1), the subsets of dendritic cells responsible for initiating cytotoxic immune responses. The increase in DC1 content and activity following local and systemic GM-CSF administration support a role for GM-CSF as an immune stimulant and vaccine adjuvant in cancer patients. GM-CSF has shown clinical activity as an immune stimulant in tumor cell and dendritic cell vaccines, and may increase antibody-dependent cellular cytotoxicity. The successful use of myeloid acting cytokines to enhance anti-tumor responses will likely require the utilization of GM-CSF in combination with cytotoxic or other targeted therapies.Keywords: GM-CSF, G-CSF, cancer, hematopoietic cytokines Martha ArellanoSagar LonialDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 13-27 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Martha Arellano Sagar Lonial Clinical uses of GM-CSF, a critical appraisal and update
description	Martha Arellano, Sagar LonialEmory University, Winship Cancer Institute, Atlanta, GA, USAAbstract: The role of granulocyte-macrophage-colony-stimulating factor (GM-CSF) in the supportive care of cancer patients has been evaluated with promising results. More recently, GM-CSF has been added to regimens for the mobilization of hematopoietic progenitor cells. An expanding role for GM-CSF in regulating immune responses has been recognized based upon its activity on the development and maturation of antigen presenting cells and its capability for skewing the immune system toward Th1-type responses. GM-CSF has been shown to preferentially enhance both the numbers and activity of type 1 dendritic cells (DC1), the subsets of dendritic cells responsible for initiating cytotoxic immune responses. The increase in DC1 content and activity following local and systemic GM-CSF administration support a role for GM-CSF as an immune stimulant and vaccine adjuvant in cancer patients. GM-CSF has shown clinical activity as an immune stimulant in tumor cell and dendritic cell vaccines, and may increase antibody-dependent cellular cytotoxicity. The successful use of myeloid acting cytokines to enhance anti-tumor responses will likely require the utilization of GM-CSF in combination with cytotoxic or other targeted therapies.Keywords: GM-CSF, G-CSF, cancer, hematopoietic cytokines
format	article
author	Martha Arellano Sagar Lonial
author_facet	Martha Arellano Sagar Lonial
author_sort	Martha Arellano
title	Clinical uses of GM-CSF, a critical appraisal and update
title_short	Clinical uses of GM-CSF, a critical appraisal and update
title_full	Clinical uses of GM-CSF, a critical appraisal and update
title_fullStr	Clinical uses of GM-CSF, a critical appraisal and update
title_full_unstemmed	Clinical uses of GM-CSF, a critical appraisal and update
title_sort	clinical uses of gm-csf, a critical appraisal and update
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/32953b4d00e0411a88651813463f32b8
work_keys_str_mv	AT marthaarellano clinicalusesofgmcsfacriticalappraisalandupdate AT sagarlonial clinicalusesofgmcsfacriticalappraisalandupdate
_version_	1718402766363164672

Clinical uses of GM-CSF, a critical appraisal and update

Ejemplares similares